Skip to content

SEPN

Septerna, Inc.

NASDAQ · USHealthcareBiotechnology
$32.21-3.56%

Price as of Jul 20, 2026

SEPN growth

Septerna, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
+7295.6%
EBITDA
+38.9%
EBIT
+39.0%
EPS
+59.7%
Free cash flow
+241.0%
Operating cash flow
+245.6%

Forward estimates

Revenue
-45.3%
EBITDA
+74.7%
EPS
+5.5%

Three-year CAGR

Revenue
+1644.5%
EBITDA
+33.3%
EBIT
+0.0%
Net income
+31.9%
EPS
+43.0%
Free cash flow
+257.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.